네이처셀

007390KOSDAQ기초 의약물질 제조업

66.3 / 100

Reference Date: 2026-06-10

Financial Score18.5 / 40

News Sentiment19.8 / 25

Momentum18.0 / 20

Disclosure10.0 / 15

AI Analysis: the debt ratio is very low with excellent financial health but Operating Profit is on a declining trend. Surged 56.0% over the past month, and news sentiment is positive.

Company InformationBased on 2025 Annual Report

Business Overview

NatureCell focuses on developing and selling stem cell therapies (e.g., JointStem, AstroStem), stem cell culture media, cosmetics, and beverage R&D and sales. The company is expanding its global presence through clinical trials in the U.S. and Japan, as well as a 2022 acquisition of a U.S. subsidiary. In 2024, the stem cell business accounted for approximately 68% of total revenue.

Number of Employees

83people

Average Salary

45.1M KRW

Score Calculation Basis

Detailed Financial Score

PER

—Industry Average 27.714.0Point

PBR

—Industry Average 1.743.5Point

ROE

-4.45Industry Average -6.033.5Point

Below industry avg

Debt Ratio

4.76Industry Average 6.625.0Point

Lower than industry avg (good)

Trend 2023~20252.5 / 10 points

Revenue Growth Rate

2.5 / 3

Avg ▲15.6% (2-year basis)

Operating Profit Growth Rate

0.0 / 3

Avg ▼302.2% (2-year basis)

ROE Trend

0.0 / 4

Avg ROE -7.4% (improving, 3yr)

Detailed News Sentiment

6 totalPositive 5Neutral 1Negative 0Average Sentiment Score 79.2

Neutral
[서울데이터랩]개장 직후 인기 검색 종목 20選
Positive
네이처셀, 연이틀 상한가…디앤디파마텍도 간생검 공개 앞두고 ‘강세...
네이처셀이 상한가를 기록하며 관련 기업 디앤디파마텍의 긍정적 전망으로 인해 시장 전반에 긍정적인 영향을 미쳤다.
Positive
[ET특징주]네이처셀, 줄기세포 치료제 美 FDA 정식 허가 신청 가능...
네이처셀의 줄기세포 치료제가 미국 FDA 정식 허가 신청 가능 소식으로 인해 주가가 급등했다.

Detailed Momentum

52-week position6.0Point

52w upper range (61%)

Current 29,700Won52-week high 37,80052-week low 16,900

1-month return6.0Point

1m +55.99% (strong rise)

Volume trend6.0Point

Volume surge

Detailed Disclosure

2 totalPositive 0Neutral 2Negative 0

Neutral기업설명회(IR)개최2026-06-05
Neutral분기보고서 (2026.03)2026-05-15